EPICODE
Financiado
Programmable Readers Writers and Erasers of the Epigenetic Cytosine Code
Human DNA contains two types of biologically instructive information: the canonical nucleobases A, G, T, C, and the epigenetic nucleobases mC, hmC, fC, and caC. Canonical nucleobases encode the identity of all RNAs and proteins th...
Human DNA contains two types of biologically instructive information: the canonical nucleobases A, G, T, C, and the epigenetic nucleobases mC, hmC, fC, and caC. Canonical nucleobases encode the identity of all RNAs and proteins that are synthesized by a cell, whereas epigenetic nucleobases regulate this synthesis. This regulation shapes the phenotype of cells, and its perturbation is a key trigger of cancer.
Canonical nucleobases can be decoded in a programmable manner by nucleic acids and their analogs via Watson-Crick-base pairing, and the simplicity of this recognition has enabled revolutionary developments in the biological sciences. In contrast, comparable developments in epigenetics have not yet been possible, since a molecular scaffold with programmable recognition of epigenetic nucleobases does not exist.
We will establish the first class of molecules capable of the expanded programmable recognition of both canonical and epigenetic DNA nucleobases in vitro and in vivo. This is based on transcription-activator-like effectors (TALEs) that consist of four types of concatenated modules, each of which recognizes a canonical nucleobase. We have recently reported the detection of single epigenetic nucleobases by TALEs.
In this project, we will
1. engineer a toolbox of TALE modules with selectivity for C, mC, hmC, fC, and caC,
2. employ them for TALE-based in vitro typing and profiling (reading) of cancer biomarker mC/hmC, and
3. design photoactivatable TALE-fusions that enable the writing and erasing of mC at user-defined genomic loci in vivo with spatiotemporal resolution. This will provide the first insights into the dynamic effects of de novo editing on chromatin regulation, and enables the imprinting of regulatory states.
Given the central role of epigenetic nucleobases in cancer and the universality of our approach, this project will provide enabling and broadly applicable methodology for cancer epigenetics research, diagnosis and therapy.
ver más
Duración del proyecto: 72 meses
Fecha Inicio: 2017-04-22
Fecha Fin: 2023-04-30
Fecha Fin: 2023-04-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2023-04-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2016-COG:
ERC Consolidator Grant
Cerrada
hace 8 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
TECHNISCHE UNIVERSITAT DORTMUND
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
11.11M€ |
Participante